Platform companies have shown great ability to create shareholder value as they roll out multiple clinical candidates based on the same technology. After securing a stellar licensing deal, we believe that the company will rapidly expand its pipeline with new candidates and deals as it now has a full war chest and the independent validation provided by oncology giant Genentech. We reinitiate our buy recommendation with a TP of NOK 130.
